BANK OF AMERICA CORP /DE/ - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 1 filers reported holding AIMMUNE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q3 2020$5,794,000
-47.8%
168,202
-74.7%
0.00%
-50.0%
Q2 2020$11,096,000
+85.7%
664,130
+60.2%
0.00%
+100.0%
Q1 2020$5,975,000
-59.3%
414,455
-5.6%
0.00%
-50.0%
Q4 2019$14,696,000
+90.0%
439,100
+18.9%
0.00%
+100.0%
Q3 2019$7,735,000
+44.7%
369,414
+43.8%
0.00%0.0%
Q2 2019$5,346,000
-15.3%
256,822
-9.1%
0.00%0.0%
Q1 2019$6,315,000
-50.3%
282,559
-46.8%
0.00%
-50.0%
Q4 2018$12,702,000
-10.0%
531,055
+2.6%
0.00%0.0%
Q3 2018$14,113,000
+78.4%
517,376
+75.9%
0.00%
+100.0%
Q2 2018$7,909,000
+1.0%
294,106
+19.5%
0.00%0.0%
Q1 2018$7,832,000
+7.1%
246,058
+27.2%
0.00%0.0%
Q4 2017$7,314,000
+2.0%
193,423
-33.1%
0.00%0.0%
Q3 2017$7,171,000
+67.3%
289,266
+38.7%
0.00%0.0%
Q2 2017$4,286,000
+2.8%
208,492
+8.7%
0.00%0.0%
Q1 2017$4,169,000
+41.1%
191,885
+32.8%
0.00%0.0%
Q4 2016$2,955,000
+44.4%
144,507
+5.9%
0.00%
Q3 2016$2,046,000
+40.8%
136,447
+1.6%
0.00%
Q2 2016$1,453,000
-26.3%
134,280
-7.7%
0.00%
Q1 2016$1,972,000
+587.1%
145,420
+833.5%
0.00%
Q4 2015$287,000
+31.7%
15,578
+80.7%
0.00%
Q3 2015$218,0008,6190.00%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Foresite Capital Management II, LLC 3,100,146$117,248,00040.96%
TLP GROUP LLC 1,050,000$39,711,00027.53%
Aisling Capital LLC 2,240,000$84,717,00016.74%
Foresite Capital Management III, LLC 764,824$28,926,0008.12%
AlpInvest Partners B.V. 51,498$1,948,0006.95%
Vivo Capital, LLC 643,626$24,342,0005.21%
GREAT POINT PARTNERS LLC 573,550$21,692,0003.70%
Eventide Asset Management 1,226,000$46,367,0002.42%
Palo Alto Investors LP 1,146,419$43,358,0001.87%
HAMILTON LANE ADVISORS LLC 78,846$2,982,0001.54%
View complete list of AIMMUNE THERAPEUTICS INC shareholders